Revolution Medicines (NASDAQ: RVMD) director sells 5,580 shares, exercises options

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Revolution Medicines director Sushil Patel reported option exercises and share sales in RVMD stock. On June 29, 2026, he exercised stock options to acquire 2,955 shares of common stock at an exercise price of $37.54 per share and sold 5,580 shares in a series of open-market transactions.

The sales were executed at weighted-average prices within ranges from $182.93 to $192.64 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. After these transactions, Patel directly held 27,236 common shares, including 1,191 restricted stock units.

Insights

Patel’s Form 4 shows a planned option exercise and modest net share sale.

Director Sushil Patel exercised options for 2,955 shares at an exercise price of $37.54 and sold 5,580 shares of Revolution Medicines common stock in multiple open-market trades on June 29, 2026. The filing shows a mix of acquisition and disposition activity.

A footnote states the transactions were made under a Rule 10b5-1 trading plan adopted on March 30, 2026, indicating the trades were pre-scheduled rather than opportunistic. Following the transactions, Patel held 27,236 shares directly, including 1,191 restricted stock units, suggesting he retains a meaningful equity stake.

Insider Trade Summary 10b5-1

Net Seller: 5,580 shares ($1,048,967)

Net Sell 11 txns

Insider Patel Sushil

Role null

Sold 5,580 shs ($1.05M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,955	$0.00	--
Exercise	Common Stock	2,955	$37.54	$111K
Sale	Common Stock	300	$183.1733	$55K
Sale	Common Stock	900	$184.5869	$166K
Sale	Common Stock	1,100	$185.8991	$204K
Sale	Common Stock	858	$186.9157	$160K
Sale	Common Stock	300	$187.8267	$56K
Sale	Common Stock	100	$188.57	$19K
Sale	Common Stock	600	$190.545	$114K
Sale	Common Stock	541	$191.8661	$104K
Sale	Common Stock	881	$192.6139	$170K

Holdings After Transaction: Stock Option (Right to Buy) — 13,000 shares (Direct, null); Common Stock — 27,236 shares (Direct, null)

Footnotes (1)

Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. Includes 1,191 restricted stock units. The transaction was executed in multiple trades in prices ranging from $182.93 to $183.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $184.08 to $184.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $185.37 to $186.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $186.38 to $187.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $187.46to $188.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $190.44 to $190.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $191.47 to $192.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $192.55 to $192.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Fully vested.

Key Figures

Shares sold: 5,580 shares Option shares exercised: 2,955 shares Exercise price: $37.54 per share +5 more

8 metrics

Shares sold 5,580 shares Total common shares sold in open-market transactions on June 29, 2026

Option shares exercised 2,955 shares Common shares acquired via stock option exercise on June 29, 2026

Exercise price $37.54 per share Exercise price for stock options converted into 2,955 common shares

Sale price ranges $182.93–$192.64 per share Price ranges for multiple open-market sale trades reported in footnotes

Post-transaction holdings 27,236 shares Common shares directly held by Patel after transactions, including RSUs

Restricted stock units 1,191 RSUs Restricted stock units included within Patel’s reported share holdings

Rule 10b5-1 plan adoption date March 30, 2026 Date Patel adopted the trading plan governing these transactions

Option expiration June 19, 2034 Expiration date for the stock option covering 2,955 shares

Key Terms

Rule 10b5-1 trading plan, restricted stock units, weighted average sale price, Stock Option (Right to Buy), +2 more

6 terms

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"Includes 1,191 restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported in Column 4 above reflects the weighted average sale price."

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

open-market sale financial

"Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 06:25 PM Accepted by SEC EDGAR 07/01/2026 - 06:25 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Sushil

(Last)

(First)

(Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DR

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/29/2026		M⁽¹⁾		2,955	A	$37.54	27,236⁽²⁾	D
Common Stock	06/29/2026		S⁽¹⁾		300	D	$183.1733⁽³⁾	26,936⁽²⁾	D
Common Stock	06/29/2026		S⁽¹⁾		900	D	$184.5869⁽⁴⁾	26,036⁽²⁾	D
Common Stock	06/29/2026		S⁽¹⁾		1,100	D	$185.8991⁽⁵⁾	24,936⁽²⁾	D
Common Stock	06/29/2026		S⁽¹⁾		858	D	$186.9157⁽⁶⁾	24,078⁽²⁾	D
Common Stock	06/29/2026		S⁽¹⁾		300	D	$187.8267⁽⁷⁾	23,778⁽²⁾	D
Common Stock	06/29/2026		S⁽¹⁾		100	D	$188.57	23,678⁽²⁾	D
Common Stock	06/29/2026		S⁽¹⁾		600	D	$190.545⁽⁸⁾	23,078⁽²⁾	D
Common Stock	06/29/2026		S⁽¹⁾		541	D	$191.8661⁽⁹⁾	22,537⁽²⁾	D
Common Stock	06/29/2026		S⁽¹⁾		881	D	$192.6139⁽¹⁰⁾	21,656⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$37.54	06/29/2026		M⁽¹⁾			2,955	⁽¹¹⁾	06/19/2034	Common Stock	2,955	$0	13,000	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026.

2. Includes 1,191 restricted stock units.

3. The transaction was executed in multiple trades in prices ranging from $182.93 to $183.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

4. The transaction was executed in multiple trades in prices ranging from $184.08 to $184.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

5. The transaction was executed in multiple trades in prices ranging from $185.37 to $186.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

6. The transaction was executed in multiple trades in prices ranging from $186.38 to $187.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

7. The transaction was executed in multiple trades in prices ranging from $187.46to $188.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

8. The transaction was executed in multiple trades in prices ranging from $190.44 to $190.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

9. The transaction was executed in multiple trades in prices ranging from $191.47 to $192.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

10. The transaction was executed in multiple trades in prices ranging from $192.55 to $192.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

11. Fully vested.

	/s/ Jack Anders, as Attorney-in-fact for Sushil Patel	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did RVMD director Sushil Patel report on June 29, 2026?

Sushil Patel reported exercising options for 2,955 Revolution Medicines shares and selling 5,580 common shares on June 29, 2026. The sales occurred in multiple open-market trades at prices mainly between $182.93 and $192.64 per share, according to the Form 4 filing.

Were Sushil Patel’s RVMD stock sales under a Rule 10b5-1 trading plan?

Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026. Such plans pre-schedule trades, indicating the timing was arranged in advance rather than based on short-term market conditions.

How many Revolution Medicines shares did Sushil Patel sell and at what prices?

Patel sold 5,580 shares of Revolution Medicines common stock in several open-market transactions. Footnotes show the trades were executed in price ranges from $182.93 up to $192.64 per share, with the reported prices reflecting weighted-average sale prices within those ranges.

How many Revolution Medicines shares does Sushil Patel hold after these transactions?

After the June 29, 2026 transactions, Sushil Patel directly held 27,236 shares of Revolution Medicines common stock. This total includes 1,191 restricted stock units, which are share-based awards that typically vest over time according to the company’s equity compensation terms.

What stock options did Sushil Patel exercise in the latest RVMD Form 4?

Patel exercised stock options covering 2,955 shares of Revolution Medicines common stock at an exercise price of $37.54 per share. A related derivative entry describes a stock option (right to buy) tied to these underlying shares, with the option expiring on June 19, 2034.